Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to
announce it has secured licenced a patented science based
nutraceutical formulation that addresses major points of viral
invasion, replication and toxicities develop by Dr. Dana F. Flavin,
an internationally-recognized expert in immune modulation and the
prevention and treatment of viruses and cancer.
A NATURAL MULTIPLE PATHWAY APPROACH IN
ADDRESSING VIRAL INFECTIONS
The patented formulation developed by Dr. Dana
F. Flavin, which will be marketed under the Company’s Bioganix
brand, was developed to work with multiple pathways to combat viral
infections, including COVID-19, by increasing the antiviral defense
while decreasing the replication and toxicity of the virus.
According to Dr. Dana Flavin, the most important
aspect of a multiple pathway approach is synergy – a process in
which some substances cooperate to reach a combined effect that is
greater than the sum of their separate effect. Synergy is not only
important in the development of a specific effective formulation,
but also as an adjunct to conventional drug therapy.
The patented formulation was designed the
address viral infections through a synergistic interaction of
several natural and GRAS ingredients that amplify effect of
ingredients working with enhanced supportive mechanisms, which show
greater efficacies based on their expansion of the biochemical
processes and pharmacological activities.
THE RIGHT NATURAL
INGREDIENTS
Based on research about specific ingredients,
the following natural substances offer important benefits in the
prevention and treatment of viral infection such as COVID-19. When
combined, their qualities are amplified for effectiveness.
N-acetylcysteine (NAC) added
for its ability proven in clinical studies to increase lymphocytes
that contain interferon. Lymphocytes are often suppressed in viral
infections like COVID-19. These cells that release interferon are
part of the Th1 lymphocytes important for their antiviral activity.
One of the mechanisms in this lymphocyte suppression is the
generation of a gas, nitric oxide. This gas comes from an enzyme,
nitric oxide synthase, and is elevated in viral infections. NAC
binds to this gas and allows the movement of these lymphocytes back
into the blood stream and an increased antiviral activity of these
Th1 lymphocytes. Additionally, NAC increases the endogenous
anti-inflammatory factor, glutathione, in the lung tissue.
Olive Leaf Extract and Licorice
Root added for their ability proven in clinical studies to
increase the release of interferon. One of the most important
mechanisms in viral defense is to increase interferon, which works
directly against virus replication and/or invasion. Many natural
substances increase the release of interferon. Combined, olive leaf
extract and licorice root are the most effective natural substances
to increase this release of interferon from the lymphocytes. Olive
leaf contains essential substances like polyphenols including
oleuropein, which increases the release of interferon lymphocytes.
Olive leaf also increases the absolute numbers of the CD8+ and
natural killer cells to improve the defense against viral
infections. Additionally, licorice root with its glycyrrhinic acid,
increases the release of interferon. Licorice root has been used
for hundreds of years to fight upper respiratory viruses.
Zinc added for its ability
proven in clinical studies to increase the efficacy of interferon.
Zinc is a known trace element that is imperative for the immune
system where it improves the host response to many infections and
plays an important role in the homeostasis of the immune system. In
the cases of viral infection, it increases the interferon efficacy
to a multiple as much as 10-fold as well as having direct antiviral
activities. Zinc supplementation decreases the morbidity of lower
respiratory tract infections in pediatric patients in the
developing world. In respiratory syncytial virus infections, for
example, zinc prevents the replication of the virus. With
rhinoviruses, zinc appears to inhibit the direct binding of the
virus. Zinc also inhibits the replication of human immunodeficiency
virus type I (HIV-1); herpes simplex virus (HSV); 0020vaccinia
virus; and polioviruses.
Elderberry, Vitamin C, and Lemon
Balm added for their ability proven in clinical studies to
inhibit viral replication. One of the important nuclear
transcription factors involved in viral replication in coronavirus
infections is nuclear factor kappa B (NFKappaB). This key
transcription factor activates numerous genes involved in cellular
immune response and inflammation. Many studies have shown that
NF-kappa B plays an important role in the pathogenesis of lung
diseases, and therefore, is important to inhibit this nuclear
factor in preventing and/or supporting patients with COVID-19.
There are many antioxidants that inhibit this important factor in
viral replication. The most important ones are Vitamin C, lemon
balm and elderberry -- natural substances that inhibit viral
replication through their inhibition of NFKappaB. Additional
mechanisms that fight against viral infections include direct and
indirect immune activation, inhibition of viral replication, and
even down regulating toxic oxygen radicals involved in cell damage
from viruses.
Cherry Extract, Rose Hips and
Nicotinamide added for their ability proven in clinical
studies to inhibit the oxygen radicals. The damage caused by oxygen
radicals in viral infections has been known for many years. The
major enzymes involved in this toxicity are xanthine oxidase (XO),
NADPH oxidase and inducible nitric oxide synthase (iNOS). The
superoxide radical, generated from XO and/or NADPH OX combine with
the nitric oxide generated from the iNOS to form the toxic product,
peroxynitrite. Viruses, including coronaviruses, are toxic via this
pathway. These radicals are massively destructive to tissues where
they are generated. In the case of COVID-19, this involves
predominantly the lung tissue, causing a decrease in oxygen
transfer leading to major lung toxicity and hypoxia in multiple
organs.
PARTERSHIP FOR DEVELOPMENT AND INITIAL
EXCLUSIVITY
The Company has partnered with the licensor, a
Canadian company engaged in the research and development of
proprietary Nutraceutical products, Intellectual properties and
other related formulas for the health and wellness, nutraceutical
industries and the general public, to develop a strategy for brand
development, messaging and retail distribution.
Licensor has granted the Company an initial
exclusive license for the UNITED STATES, GERMANY and COLOMBIA to
use the Licensed Product and the Licensor Intellectual Property to
manufacture, have manufactured and sell the Licensed Product,
provided that the Licensed Product is manufactured in accordance
with the specifications and quality standards submitted or approved
by Licensor.
Licensor grants licenses and rights to the IP
Rights and Marks through a base revenue share per unit sold of
three dollars. The Company has also agreed that the licensor will
be working in partnership with the Company to engage a third party
or parties at it sole discretion , time and place for the
purpose of marketing, selling and promoting of such licensed
products through major retail chains where in this case that such
collaboration will result in a profit margin sharing.
CEO of Relevium Aurelio Useche stated, “We are
extremely excited to have secured the exclusive license for this
100% natural synergistic and multi-pathway patented formulation,
which we will be launching in the market over the next months. This
is a major addition to the CleanCare product portfolio adding
prevention and immunity support to the Bioganix line of trusted
nutraceuticals”
About Relevium Technologies
Relevium is a publicly traded Company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition, and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical Company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian and United
States securities laws. All statements in this news release, other
than statements of historical facts, including statements regarding
future estimates, plans, objectives, assumptions, or expectations
of future performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", or "would" occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.comWebsite: www.releviumtechnologies.comLike
us on FacebookFollow us on TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024